Please try another search
For the six months ended 30 June 2016, Tobira Therapeutics Inc revenues increased from $0K to $1.2M. Net loss increased 42% to $25.6M. Revenues reflect Collaboration revenue increase from $0K to $107K. Higher net loss reflects Research and development increase of 59% to $19.6M (expense), Change in fair value of preferred stock decrease from $1.9M (income) to $0K, General and administrative increase of 23% to $6.5M (expense).
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Total Revenue | 1.06 | 0.11 | 0 | 0 |
Gross Profit | ||||
Operating Income | -12.95 | -11.91 | -9.07 | -26.23 |
Net Income | -13.34 | -12.22 | -9.39 | -22.21 |
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Total Assets | 44.64 | 55.83 | 65.41 | 71.82 |
Total Liabilities | 24.88 | 24.09 | 22.64 | 20.49 |
Total Equity | 19.76 | 31.74 | 42.77 | 51.33 |
Period Ending: | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -21.73 | -10.09 | -31.29 | -25.2 |
Cash From Investing Activities | 0 | 0 | 33.19 | 33.2 |
Cash From Financing Activities | -0.01 | -0.01 | 54.35 | 54.44 |
Net Change in Cash | -21.74 | -10.09 | 56.25 | 62.45 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review